PDE5A and pulmonary arterial hypertension: PAH specific therapies are considered primarily as vasodilators because they block vasoconstriction (ERA) or promote vasodilation via cGMP (PDE5 inhibitors) or cAMP (prostacyclin analogues) pathways.